>via pharmatimes.com
13 medicines on Australia's Pharmaceutical Benefits Scheme (PBS), accounting for more than 200 brands, have taken new price cuts of between 11% and 77%, as part of the ongoing price disclosure scheme agreed between the government and industry group Medicines Australia.
The biggest price reduction is for GlaxoSmithKline's anti-nausea treatment Zofran (ondansetron), which is reduced by 77%, while Sanofi's cancer drug Eloxatin (oxaliplatin) will take a 51% price cut.
No comments:
Post a Comment